Enanta Pharmaceuticals (ENTA) Other financing activities (2012 - 2018)

Enanta Pharmaceuticals (ENTA) has 7 years of Other financing activities data on file, last reported at -$5.5 million in Q2 2018.

• For the quarter ending Q2 2018, Other financing activities changed N/A year-over-year to -$5.5 million; the trailing twelve-month figure through Sep 2024 stood at -$5.5 million (down 68.06% YoY), and the FY2023 full-year result was $325000.0, changed N/A from the prior year.
• Other financing activities for Q2 2018 stood at -$5.5 million, down from $2.2 million in the prior quarter.
• Across five years, Other financing activities topped out at $2.2 million in Q1 2018 and bottomed at -$5.5 million in Q2 2018.
• The 5-year median for Other financing activities is -$2000.0 (2016), against an average of -$222.22.
• The widest annual swing landed in 2015, when Other financing activities sank 160.0%; it then jumped 1767.65% in 2016.
• A 5-year view of Other financing activities shows it stood at $1.9 million in 2014, then slumped by 100.16% to -$3000.0 in 2015, then surged by 33.33% to -$2000.0 in 2016, then slumped by 12150.0% to -$245000.0 in 2017, then plunged by 2146.53% to -$5.5 million in 2018.
• The last three Other financing activities figures came in at -$5.5 million (Q2 2018), $2.2 million (Q1 2018), and -$245000.0 (Q4 2017), per Business Quant data.

Peer Comparison